XASXMDC
Market cap9mUSD
Feb 22, Last price
6.60AUD
Name
Medlab Clinical Ltd
Chart & Performance
P/E
—
P/S
1,267.12
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.39%
Rev. gr., 5y
-70.62%
Revenues
12k
-98.67%
Net income
-2m
L-68.57%
CFO
-5m
Earnings
Jan 07, 2025
Profile
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | ||||||||||
Revenues | 12 -98.67% | 892 -30.44% | 1,282 -70.85% | |||||||
Cost of revenue | 12 | 6,114 | 7,835 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (5,222) | (6,553) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (2,873) | 3,523 | ||||||||
Tax Rate | ||||||||||
NOPAT | (2,349) | (10,075) | ||||||||
Net income | (2,131) -68.57% | (6,778) -5.36% | (7,162) -41.88% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 15,449 | |||||||||
BB yield | -94.07% | |||||||||
| Debt | ||||||||||
Debt current | 568 | |||||||||
Long-term debt | 1,677 | |||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 14 | 186 | ||||||||
Net debt | (276) | (3,428) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (5,470) | |||||||||
CAPEX | (16) | (29) | ||||||||
Cash from investing activities | 983 | 1,747 | ||||||||
Cash from financing activities | (482) | (725) | ||||||||
FCF | 1,018 | (308) | (10,647) | |||||||
| Balance | ||||||||||
Cash | 226 | 5,191 | ||||||||
Long term investments | 50 | 483 | ||||||||
Excess cash | 231 | 5,610 | ||||||||
Stockholders' equity | 1,280 | 7,749 | ||||||||
Invested Capital | 1,062 | 3,448 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 2,284 | 2,284 | 2,281 | |||||||
Price | 7.20 -66.90% | |||||||||
Market cap | 16,424 -61.58% | |||||||||
EV | 12,663 | |||||||||
EBITDA | (4,778) | (6,553) | ||||||||
EV/EBITDA | ||||||||||
Interest | 527 | 33 | 45 | |||||||
Interest/NOPBT | ||||||||||